Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

DISEASE CHARACTERISTICS:

* Histologically confirmed non-small cell lung cancer

  * No squamous cell carcinoma
  * No histology in close proximity to a major vessel
* Resectable stage IB-IIIA disease
* No CNS or brain metastases

PATIENT CHARACTERISTICS:

* ECOG performance status 0-1
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 8.0 g/dL
* Bilirubin normal
* Creatinine ≤ 1.5 mg/dL
* Urine protein:creatinine \< 1.0
* Alkaline phosphatase (AP), AST, and ALT must meet 1 of the following criteria:

  * AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)
  * AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN
  * AP ≤ 5 times ULN AND AST and ALT normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment
* Adequate pulmonary and cardiovascular function to tolerate surgical resection
* No cavitation or history of hemoptysis (i.e., bright red blood ≥ ½ teaspoon)
* No existing peripheral neuropathy ≥ grade 1
* No known history of severe hypersensitivity reaction to drugs formulated with polysorbate 80
* No history of serious systemic disease, including any of the following:

  * Myocardial infarction within the past 6 months
  * Uncontrolled hypertension (i.e., blood pressure \> 150/110 mm Hg on medication)
  * Unstable angina
  * New York Heart Association class II-IV congestive heart failure
  * Unstable symptomatic arrhythmia requiring medication

    * Patients with chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are eligible
  * Clinically significant peripheral vascular disease (i.e., grade II or higher)
* No history of significant neurological or psychiatric condition
* No known active infection within the past 14 days
* No serious, nonhealing wound, ulcer, or bone fracture
* No evidence of bleeding diathesis or coagulopathy
* No stroke within the past 6 months
* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
* No other serious illness or medical condition
* No active infection
* No other currently active malignancy except nonmelanoma skin cancer

  * Malignancies for which therapy has been completed and are considered to have ≤ 30% chance of risk of relapse are not considered active

PRIOR CONCURRENT THERAPY:

* No prior chemotherapy or VEGF inhibitor
* No prior (i.e., within the past 4 weeks), concurrent, or anticipated participation in another experimental drug study except a Genentech-sponsored bevacizumab cancer study
* No major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days
* No anticipation for major surgical procedure during study treatment
* No fine-needle aspiration or core biopsy within 7 days prior to study entry
* No concurrent full-dose anticoagulation
* No other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy for this cancer